ProPhase Labs, Inc. Proceeds from Notes Payable
ProPhase Labs, Inc. (PRPH) reported Proceeds from Notes Payable of $493.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-19
- ProPhase Labs, Inc. proceeds from notes payable for the quarter ending 2026-06-30 was $205.00K, a 57.56% decline year-over-year.
- ProPhase Labs, Inc. proceeds from notes payable for the quarter ending 2026-03-31 was $288.00K, a 41.18% increase year-over-year.
- ProPhase Labs, Inc. proceeds from notes payable for the quarter ending 2025-12-31 was $1.16M, a 24.08% decline year-over-year.
- ProPhase Labs, Inc. proceeds from notes payable for the quarter ending 2025-09-30 was $2.23M, a 50.13% decline year-over-year.
- ProPhase Labs, Inc. proceeds from notes payable for fiscal 2025 was $4.07M, a 58.69% decline from fiscal 2024.
- ProPhase Labs, Inc. proceeds from notes payable for fiscal 2024 was $9.86M, a 29.76% increase from fiscal 2023.
- ProPhase Labs, Inc. proceeds from notes payable for fiscal 2023 was $7.60M.
- ProPhase Labs, Inc. proceeds from notes payable for fiscal 2022 was $0.00.
| Period end | Proceeds from Notes Payable 0 month | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $205.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $493.00K 10-Q · filed 2026-08-19 | $1.65M derived: sum of 3 quarters · filed 2026-08-19 | $3.88M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2026-03-31 | $288.00K 10-Q/A · filed 2026-07-09 | $1.45M derived: sum of 2 quarters · filed 2026-07-09 | $3.67M derived: sum of 3 quarters · filed 2026-07-09 | $4.16M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $3.39M derived: sum of 2 quarters · filed 2026-06-01 | $3.87M derived: sum of 3 quarters · filed 2026-08-19 | $4.07M 10-K · filed 2026-06-01 | ||
| 2025-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $2.71M derived: sum of 2 quarters · filed 2026-08-19 | $2.91M 10-Q · filed 2025-11-19 | $4.44M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-06-30 | $483.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $687.00K 10-Q · filed 2026-08-19 | $2.21M derived: sum of 3 quarters · filed 2026-08-19 | $6.68M derived: sum of 4 quarters · filed 2026-08-19 | ||
| 2025-03-31 | $204.00K 10-Q/A · filed 2026-07-09 | $1.73M derived: sum of 2 quarters · filed 2026-07-09 | $6.20M derived: sum of 3 quarters · filed 2026-07-09 | $7.61M derived: sum of 4 quarters · filed 2026-07-09 | ||
| 2024-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $5.99M derived: sum of 2 quarters · filed 2026-06-01 | $7.40M derived: sum of 3 quarters · filed 2026-06-01 | $9.86M 10-K · filed 2026-06-01 | ||
| 2024-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $5.87M derived: sum of 2 quarters · filed 2025-11-19 | $8.33M 10-Q · filed 2025-11-19 | $8.33M derived: sum of 4 quarters · filed 2025-11-19 | ||
| 2024-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $3.87M 10-Q · filed 2025-08-13 | $3.87M derived: sum of 3 quarters · filed 2025-08-13 | $3.87M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $2.46M 10-Q · filed 2025-05-20 | $2.46M derived: sum of 2 quarters · filed 2025-05-20 | $2.46M derived: sum of 3 quarters · filed 2025-05-20 | $2.46M derived: sum of 4 quarters · filed 2025-05-20 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $0.00 derived: sum of 2 quarters · filed 2025-04-01 | $0.00 derived: sum of 3 quarters · filed 2025-04-01 | $7.60M 10-K · filed 2025-04-01 | $10.52M 10-K · filed 2024-03-29 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $7.60M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $7.60M 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | $7.60M 10-Q · filed 2024-05-10 | |||||
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 | |||||
| 2015-12-11 | $1.50M 10-Q/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |